Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ: COSM) announced significant developments on April 9, 2025, as its subsidiary, Cana Laboratories, has completed upgrades to its manufacturing facility and secured a pivotal five-year contract with Pharmex S.A. This agreement establishes the production of 300,000 bottles annually of the antiseptic drug AMBITASOL 1L, amounting to a total of 1.5 million units over the contract's lifespan.
Cana Laboratories, which Cosmos Health acquired in July 2023, is situated in Athens and operates under European Good Manufacturing Practices (GMP) with certification from the European Medicines Agency (EMA). The recent facility upgrades aim to enhance its manufacturing capabilities, enabling Cana to produce a diverse array of products, including tablets, capsules, creams, and biocides. This expansion aligns with Cosmos Health's broader strategy to increase revenue through contract manufacturing for both its own products and third-party clients.
Greg Siokas, CEO of Cosmos Health, emphasized the importance of this collaboration with Pharmex, highlighting it as a key move to scale their contract manufacturing operations, strengthen cash flow, and augment profitability. Pharmex, a specialty pharmaceutical firm established in 1981, focuses on medicinal products and medical devices across various therapeutic fields like dermatology and pediatrics.
Cosmos Health continues to diversify and expand its global reach in the healthcare sector, boasting a portfolio of pharmaceutical and nutraceutical brands and partnerships aimed at addressing major health issues such as obesity and diabetes. With a strategic foothold in Europe, Asia, and North America, the company's initiatives reflect its commitment to innovation in the healthcare market, alongside ventures into telehealth through ZipDoctor, Inc.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ:COSM) has recently announced significant developments that merit attention from investors. The completion of upgrades at its subsidiary, Cana Laboratories, will potentially enhance its manufacturing capabilities, aligning with heightened demand for health-related products. Notably, the five-year contract agreement with Pharmex for the production of 1.5 million bottles of AMBITASOL brings not only diversification to Cosmos Health’s revenue streams but also solidifies the company's footprint in the antiseptic market.
The integration of Pharmex, a company with established roots in the specialty pharmaceutical sector, presents an opportunity for Cosmos Health to leverage its resources for innovative product offerings. Given that Cana's facilities are GMP-certified and EMA-approved, the company is positioned to expand its high-margin contract manufacturing sector, a strategic move that could lead to increased profits.
Investors should view these advancements as an indicator of Cosmos Health's growing operational capacity and market presence. The anticipated revenue growth from both proprietary brands and contract manufacturing agreements supports a bullish stance when evaluating the company's prospects. As highlighted by CEO Greg Siokas, the company is focusing on scaling up its operations while enhancing cash flows, which are essential for long-term sustainability.
However, potential investors should remain cautious. The company's forward-looking statements are fraught with uncertainties, including market volatility and potential regulatory challenges. The environment can be influenced by macroeconomic factors, including geopolitical tensions, which may affect operations.
In conclusion, Cosmos Health's recent developments indicate robust growth potential, particularly in contract manufacturing within the pharmaceutical sector. Prudent investors may consider adding COSM to their portfolios while recognizing the inherent risks associated with the healthcare market. Diversification across product offerings and geographic regions will continue to be critical as the company aims for sustained profitability and market expansion.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, April 09, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories (“Cana”), has completed the latest upgrades to its manufacturing capabilities and capacity, and has secured a long-term, five-year contract manufacturing agreement with Pharmex S.A. (“Pharmex”) for the annual production of 300,000 bottles of the antiseptic drug AMBITASOL 1L, totaling 1,500,000 units over the duration of the agreement.
Pharmex, established in 1981, is a privately held specialty pharmaceutical company focused on the commercialization and marketing of medicinal products, antiseptics, dermocosmetics, and medical devices in targeted therapeutic areas such as dermatology, ophthalmology, and pediatrics.
Cosmos Health completed its acquisition of Cana in July 2023 and has since invested in upgrading Cana’s Athens facility, which is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), laying the foundation for future growth. As a result, Cana is now ramping up revenue generation from manufacturing its own products as well as those of third parties. Cana’s facilities can accommodate a wide range of pharmaceuticals, including tablets, capsules, syrups, nasal sprays, creams, gels, antiseptics, and biocides. In line with this strategy, the Company has entered into the aforementioned contract manufacturing agreement with Pharmex to support its growth aspirations.
Greg Siokas, CEO of Cosmos Health, stated: "We are pleased to continue scaling our high-margin contract manufacturing business at Cana through our collaboration with Pharmex. We look forward to securing additional agreements that will further expand our client base, strengthen cash flows, and drive sustained profitability.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov ). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
How does Cosmos Holdings Inc. COSM plan to leverage its recent partnership with Pharmex to enhance its revenue generation and client base in the competitive pharmaceutical manufacturing landscape?
Given the long-term contract with Pharmex for AMBITASOL production, what are Cosmos Holdings Inc. COSM's projections for revenue growth over the next five years from this agreement?
With the upgrades made to Cana Laboratories' manufacturing capabilities, what specific types of products does Cosmos Holdings Inc. COSM anticipate introducing to the market in the near future?
What strategies does Cosmos Holdings Inc. COSM have in place to mitigate potential risks related to global supply chain disruptions, particularly in the context of ongoing geopolitical tensions that may affect its operations?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
2.67% G/L:
$0.2572 Last:
2,524,082 Volume:
$0.2525 Open:
